MIGUEL ANGEL
SERRA DESFILIS
CATEDRÁTICO/A DE UNIVERSIDAD
Hospital Universitario 12 de Octubre
Madrid, EspañaHospital Universitario 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (8)
2023
-
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602
-
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver
Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132
2017
-
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237
-
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148
-
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1
2015
-
High efficacy and safety of triple therapy in hcv genotype 1 and moderate fibrosis: A multicenter study of clinical practice in Spain
Annals of Hepatology, Vol. 14, Núm. 4, pp. 477-486
2014
-
Tratamiento de la hepatitis C en grupos de pacientes especiales
Gastroenterologia y Hepatologia, Vol. 37, Núm. S1, pp. 23-36
2010
-
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: Outcomes and factors predicting response
American Journal of Gastroenterology, Vol. 105, Núm. 10, pp. 2164-2172